275 related articles for article (PubMed ID: 30796021)
1. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Sánchez-Martínez D; Baroni ML; Gutierrez-Agüera F; Roca-Ho H; Blanch-Lombarte O; González-García S; Torrebadell M; Junca J; Ramírez-Orellana M; Velasco-Hernández T; Bueno C; Fuster JL; Prado JG; Calvo J; Uzan B; Cools J; Camos M; Pflumio F; Toribio ML; Menéndez P
Blood; 2019 May; 133(21):2291-2304. PubMed ID: 30796021
[TBL] [Abstract][Full Text] [Related]
2. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
Jiménez-Reinoso A; Tirado N; Martinez-Moreno A; Díaz VM; García-Peydró M; Hangiu O; Díez-Alonso L; Albitre Á; Penela P; Toribio ML; Menéndez P; Álvarez-Vallina L; Sánchez Martínez D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564128
[TBL] [Abstract][Full Text] [Related]
3. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
[TBL] [Abstract][Full Text] [Related]
4. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
[TBL] [Abstract][Full Text] [Related]
5. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
[TBL] [Abstract][Full Text] [Related]
6. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.
Maciocia PM; Wawrzyniecka PA; Maciocia NC; Burley A; Karpanasamy T; Devereaux S; Hoekx M; O'Connor D; Leon T; Rapoz-D'Silva T; Pocock R; Rahman S; Gritti G; Yánez DC; Ross S; Crompton T; Williams O; Lee L; Pule MA; Mansour MR
Blood; 2022 Jul; 140(1):25-37. PubMed ID: 35507686
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
8. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
[TBL] [Abstract][Full Text] [Related]
9. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains.
Dai Z; Mu W; Zhao Y; Jia X; Liu J; Wei Q; Tan T; Zhou J
Mol Ther; 2021 Sep; 29(9):2707-2722. PubMed ID: 34274536
[TBL] [Abstract][Full Text] [Related]
10. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
11. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
Mamonkin M; Rouce RH; Tashiro H; Brenner MK
Blood; 2015 Aug; 126(8):983-92. PubMed ID: 26056165
[TBL] [Abstract][Full Text] [Related]
12. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
[TBL] [Abstract][Full Text] [Related]
13. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
14. CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.
Liao C; Wang Y; Huang Y; Duan Y; Liang Y; Chen J; Jiang J; Shang K; Zhou C; Gu Y; Liu N; Zeng X; Gao X; Tang Y; Sun J
Adv Sci (Weinh); 2023 Sep; 10(27):e2207394. PubMed ID: 37485647
[TBL] [Abstract][Full Text] [Related]
15. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
16. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.
Fang KK; Lee J; Khatri I; Na Y; Zhang L
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917
[TBL] [Abstract][Full Text] [Related]
17. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
Bayón-Calderón F; Toribio ML; González-García S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
[TBL] [Abstract][Full Text] [Related]
18. The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies.
Guo Z; Zhang Y; Fu M; Zhao L; Wang Z; Xu Z; Zhu H; Lan X; Shen G; He Y; Lei P
Front Immunol; 2021; 12():652924. PubMed ID: 33854512
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
20. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Köksal H; Dillard P; Josefsson SE; Maggadottir SM; Pollmann S; Fåne A; Blaker YN; Beiske K; Huse K; Kolstad A; Holte H; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
Blood Adv; 2019 Apr; 3(8):1230-1243. PubMed ID: 30979721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
